Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Inotiv reports mixed Q4 results, eyes growth in NHP services

Inotiv's Q4 performance showed revenue growth but faced challenges from industry dynamics. The company is optimistic about growth opportunities in NHPs and other services, with a focus on margin improvements and customer base expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.

Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award

WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to focus on his position as Partner at AS Birch Grove.

Inotiv, Inc. Announces Changes to Board of Directors

The stock may have found its bottom in December 2022. Revenue jumped 400 percent in the fourth fiscal quarter, but earnings plummeted.

Inotiv: Turning Focus To Organic Growth

Inotiv's recently acquired companies cause its revenue to spike tremendously. However, the company's expenses are just as great, and not all of the largest cost items are one-time costs, meaning the company could remain unprofitable for a long time.

Inotiv: High Expenses Likely To Impair Long-Term Profitability

Inotiv, Inc. (NASDAQ:NOTV ) Q4 2022 Earnings Conference Call January 10, 2023 5:00 PM ET Company Participants Devin Sullivan - Investor Relations, The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Greetings, and welcome to the Inotiv, Inc.'s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Inotiv, Inc. (NOTV) Q4 2022 Results - Earnings Call Transcript

Provides Select First Quarter and Full Year Fiscal 2023 Financial Guidance Provides Select First Quarter and Full Year Fiscal 2023 Financial Guidance

Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2022 Financial Results

WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full year ended September 30, 2022 on Tuesday, January 10, 2023 after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results and Host Conference Call on Tuesday, January 10, 2023

Boston, Massachusetts--(Newsfile Corp. - December 28, 2022) - Block & Leviton is investigating Inotiv, Inc. (NASDAQ: NOTV) for potential securities law violations. Investors who have lost money in their Inotiv, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/notv.What is this all about?On November 17, 2022, Inotiv, Inc. filed a Form 8-K with the U.S.

Inotiv Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Inotiv, Inc. ("Inotiv" or the "Company") (NASDAQ: NOTV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Inotiv and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inotiv, Inc. - NOTV

Delays Release of Full Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2022 Delays Release of Full Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2022

Inotiv, Inc. Provides Business Update and Select Preliminary Fiscal Year 2022 Financial Results

WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today the opening of the second phase of its lab facility in Rockville, MD, the scheduled opening date of January 2023 for its pathology campus and training center in Kalamazoo, MI, and the opening and occupancy of the site expansion at its facility in Boulder, CO. These openings and expansions reflect the Company's ongoing initiatives to broaden its portfolio of pre-clinical and clinical service offerings.

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings

WEST LAFAYETTE, Ind., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced plans to close two isolator facilities in Indianapolis, Indiana, and consolidate them with existing facilities in the U.S. The Company's subsidiaries in France and the U.K. have also proposed a consolidation plan of two facilities in Gannat, France, and Blackthorn, Bicester U.K., into existing facilities.   The Company also provided an update on its previously announced site optimization plans in Virginia, Michigan, and Pennsylvania.

Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S., Intent to Consult with Employee Representatives for a Proposed Consolidation of Certain European and U.K. Sites, and Update on Site Optimization Plans in Process

WEST LAFAYETTE, Ind., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter ended September 30, 2022, on Monday, December 12, 2022, after the close of the stock market. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fourth Quarter Fiscal 2022 Financial Results and Host Conference Call on Monday, December 12, 2022

WEST LAFAYETTE, Ind., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences during the month of November:

Inotiv, Inc. to Participate in November Investor Conferences

WEST LAFAYETTE, Ind., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences during the month of September:

Inotiv, Inc. to Participate in September Investor Conferences

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Inotiv To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 23, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inotiv, Inc. ("Inotiv" or the "Company") (NASDAQ: NOTV) and reminds investors of the August 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Inotiv Investor Alert

New York, New York--(Newsfile Corp. - August 22, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Inotiv, Inc. (NASDAQ: NOTV) alleging that the Company violated federal securities laws.Class Period: September 21, 2021 to June 13, 2022Lead Plaintiff Deadline: August 22, 2022No obligation or cost to you.Learn more about your recoverable losses in NOTV:https://www.kleinstocklaw.com/pslra-1/inotiv-notv-lawsuit-loss-submission-form?id=31083&from=5

NOTV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 22, 2022 in the Class Action Filed on Behalf of Inotiv, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - August 22, 2022) - Levi & Korsinsky, LLP notifies investors in Inotiv, Inc. ("Inotiv" or the "Company") (NASDAQ: NOTV) of a class action securities lawsuit.The lawsuit on behalf of Inotiv investors has been commenced in the the United States District Court for the Northern District of Indiana. Affected investors purchased or otherwise acquired certain Inotiv, Inc. securities between September 21, 2021 and June 13, 2022.

NOTV LAWSUIT ALERT: Levi & Korsinsky Notifies Inotiv, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Los Angeles, California--(Newsfile Corp. - August 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inotiv, Inc. ("Inotiv" or "the Company") (NASDAQ: NOTV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Inotiv, Inc. with Losses to Contact the Firm

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Attention Inotiv, Inc. ("Inotiv") (NASDAQ: NOTV) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between September 21, 2021 and June 13, 2022. If you suffered a loss on your investment in Inotiv, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Inotiv Investors of a Lead Plaintiff Deadline of August 22, 2022

New York, New York--(Newsfile Corp. - August 21, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Inotiv, Inc. (NASDAQ: NOTV) between September 21, 2021 and June 13, 2022, both dates inclusive (the "Class Period"), of the important August 22, 2022 lead plaintiff deadline in the securities class action commenced by the firm.

NOTV FINAL DEADLINE TOMORROW: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Inotiv, Inc. Investors to Secure Counsel Before Important August 22 Deadline in Securities Class Action Filed by the Firm - NOTV

New York, New York--(Newsfile Corp. - August 20, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Inotiv, Inc. ("Inotiv" or the "Company") (NASDAQ: NOTV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Inotiv and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Inotiv, Inc. - NOTV

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) securities between September 21, 2021 and June 13, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On May 20, 2022, after the market closed, Inotiv disclosed that,

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Inotiv, Inc. (NOTV)

Los Angeles, California--(Newsfile Corp. - August 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inotiv, Inc. ("Inotiv" or "the Company") (NASDAQ: NOTV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Inotiv, Inc. with Losses to Contact the Firm

NEW YORK , Aug. 19, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Inotiv, Inc. (NASDAQ: NOTV). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/inotiv-inc-loss-submission-form/?id=30968&from=4 The lawsuit seeks to recover losses for shareholders who purchased Inotiv between September 21, 2021 and June 13, 2022.

News for Inotiv, Inc. Stock (NOTV)